1. When, How, and What Cell Source for Transplantation in ALL CR1 Hillard M. Lazarus, MD, FACP Professor of Medicine Director of Novel Cell Therapies University Hospitals…

PowerPoint Presentation RAYMOND WONG, MD Hong Kong Consultant of the Department of Medicine & Therapeutics, Prince of Wales Hospital Dr. Wong received his medical degree…

Slide 1 Indications for Successful Iron Overload Treatment and Monitoring: Other Anaemias Adlette Inati, MD Head, Division of Paediatric Haematology-Oncology Medical Director,…

Slide 1 Case Study: Patient with MF has Increasing Blasts, but Not Yet AML -- What to Do? John Mascarenhas, MD Myeloproliferative Disorders Program Tisch Cancer Institute,…

Slide 1 TRUDI GALLAGHER RN JURISDICTIONAL PATIENT BLOOD MANAGEMENT COORDINATOR FREMANTLE, WA AUSTRALIA [email protected] Patient Blood Management Building your foundation Slide…

When, How, and What Cell Source for Transplantation in ALL CR1 Hillard M. Lazarus, MD, FACP Professor of Medicine Director of Novel Cell Therapies University Hospitals Case…

Slide 1 טיפול מונע בילדים חולי המופיליה ד"ר גילי קנת מנהלת יחידת הקרישה שיבא, תל השומר ‹#› Optimal…

Allogeneic Hematopoietic Stem Cell Transplant in Severe Thalassemia Patients: Time to Transplant Suradej Hongeng, MD Professor of Pediatrics Faculty of Medicine Ramathibodi…

Indications for Successful Iron Overload Treatment and Monitoring: Other Anaemias Adlette Inati, MD Head, Division of Paediatric Haematology-Oncology Medical Director, Children's…

High Risk ACS: PCI & Real LIFE data EUROVISION registry Martial HAMON, MD, FESC University Hospital of Caen INSERM 744, IPL EURO-VISION EUROpean biValIrudin utiliSatION…